MAPT: Microtubule-associated protein tau
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity.
- Drugs that act on it: 6
- Approved: 0
- In phases 1 to 3: 6
- Sponsors: 6
Who is on it, and how far along
Every drug ChEMBL records acting on MAPT, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 6
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- AbbVie117%
- Biogen117%
- Eli Lilly117%
- Johnson & Johnson117%
- Roche117%
- UCB Biopharma SRL117%
| Bepranemab | Phase 2 | UCB Biopharma SRL | Antibody | Inhibitor | 1 |
| Gosuranemab | Phase 2 | Biogen | Antibody | Inhibitor | 0 |
| Posdinemab | Phase 2 | Johnson & Johnson | Antibody | Inhibitor | 0 |
| Semorinemab | Phase 2 | Roche | Antibody | Inhibitor | 0 |
| Tilavonemab | Phase 2 | AbbVie | Antibody | Inhibitor | 0 |
| Zagotenemab | Phase 2 | Eli Lilly | Antibody | Inhibitor | 0 |
| Trial | Drug | Phase | Status | Lead sponsor | First posted |
|---|---|---|---|---|---|
| A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Bepranemab | Phase 1 | Active, not recruiting | UCB Biopharma SRL | Dec 8, 2020 |
- Frontotemporal dementia0.79
- Pick disease0.76
- Supranuclear palsy, progressive, 10.74
- Progressive supranuclear palsy-parkinsonism syndrome0.71
- Atypical progressive supranuclear palsy syndrome0.71
- Late-onset Parkinson disease0.64
- Semantic dementia0.64
- Progressive supranuclear palsy0.60
- Parkinson disease0.55
- Atrial fibrillation0.47
- Dementia0.41
- Mental deterioration0.37
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1293224, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P10636, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets